Critical pathway experience at New England Medical Center

Prior research has shown that critical pathways can influence healthcare delivery and cost management. It was already known that managed care contracts often drive quality improvement initiatives in hospitals. No prior work had resolved how clinical services might integrate pathway development with high-volume care. That uncertainty drove the need to explore clinical pathways in specific service areas. This gap motivated the New England Medical Center to focus on high-cost or high-volume cases. Prior work had not fully addressed the role of pharmacists in pathway development. This uncertainty prompted the center to analyze drug therapy aspects in pathways. No prior work had resolved how patient education and compliance monitoring might support pathway success in capitated payment models.

The aim of this work was to develop critical pathways in areas where managed care contracts were sought. The specific problem involved identifying high-volume or high-cost case types for pathway analysis. This effort was motivated by the need to improve care delivery and cost efficiency. The researchers propose that pathway development should involve clinical services directly. The motivation included aligning treatment methods with cost considerations. The researchers propose that pharmacist involvement could enhance drug therapy analysis. The researchers propose that pathways should include both inpatient treatment and cost data. The researchers propose that future pathways should address both acute and nonacute disease management.

The center began pathway development in areas tied to managed care contracts. Clinical services analyzed high-volume or high-cost cases for pathway design. Pharmacists were involved in reviewing drug therapy aspects of pathways. The initial focus was on inpatient treatment and associated costs. The researchers propose that pathways should integrate disease treatment methods and cost data. The researchers propose that pathways should evolve to include acute and nonacute disease. The researchers propose that patient education and compliance monitoring are essential. The researchers propose that these efforts should align with a capitated payment model.

The center found that pharmacist involvement improved drug therapy analysis in pathways. Initial pathways focused on inpatient treatment and included disease treatment methods. The researchers found that pathways should integrate both treatment and cost data. The researchers found that pathways should address both acute and nonacute disease. The researchers found that patient education and compliance monitoring are vital. The researchers found that pathways should be developed by clinical services directly. The researchers found that pathway development should evolve over time. The researchers found that these efforts should support capitated payment environments.

The authors state that pharmacist involvement enhances drug therapy analysis in pathways. The authors state that pathways should integrate treatment methods and cost data. The authors state that pathways should address both acute and nonacute disease. The authors state that patient education and compliance monitoring are essential. The authors state that pathways should be developed by clinical services directly. The authors state that pathway development should evolve over time. The authors state that these efforts should align with a capitated payment model. The authors state that these findings should guide future pathway development.